InVitae (NVTA) Tops Q4 EPS by 2c, Revenues Miss

InVitae (NYSE: NVTA) reported Q4 EPS of ($0.63), $0.02 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $66.29 million versus the consensus estimate of $68.14 million.

"In 2019, we delivered another year of extraordinary growth, both in the U.S. and internationally. We expanded our customer base and saw strong re-order rates among new accounts. We also made it easier to access our testing, both through traditional payers and via unique partnership programs," said Sean George, co-founder and chief executive officer of Invitae. "We enter 2020 with momentum and a unique business model that we believe is well-positioned to deliver genetics-informed healthcare to patients. As we continue to scale our business, we are confident our approach and the investments we are making will further strengthen our ability to bring affordable, accessible genetic information to billions of people worldwide."

For earnings history and earnings-related data on InVitae (NVTA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Hyperscale Data sells 685 Bitcoin for $43M to fund Michigan data center
• Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c